At-home blood diagnostic tech gets EU nod

Personalized health technology company Thorne HealthTech (NASDAQ: THRN) has received CE Mark certification for its NanoDrop device, meaning that it meets the performance, safety, and product requirements of the European Union.

The company says that NanoDrop brings “virtually painless” blood collection to decentralized clinical trials and at-home diagnostic testing. The device uses Thorne’s dual nano lancet technology to obtain capillary whole-blood samples. NanoDrop’s CE mark certification paves the way for new testing applications by allowing individuals to use the device in their home.

Thorne, which aims to empower individuals to achieve healthy aging, uses testing and data to deliver personalized solutions that help individuals take a proactive and actionable approach to improve and maintain their health over a lifetime.

“We consistently continue to find ways to improve the blood draw experience, and with the dual nano lancet technology being a key part of the blood collection process, we look forward to making NanoDrop available across the European Union, which will allow more customers to experience and benefit from it,” said Paul Jacobson, CEO of Thorne HealthTech. “We believe this incremental news, combined with prior OneDraw clearance in Japan, puts Thorne one step closer to achieving broad application across end-markets around the globe.”

NanoDrop is developed by Drawbridge Health, which was acquired by Thorne in 2021.

“The NanoDrop offers companies the opportunity to integrate our tried-and-true dual lancet technology into a much broader array of testing and sample collection applications by making for seamless integration and a better user experience,” said Jerome Scelza, co-CEO of Drawbridge Health. “We specifically wanted to ensure the broadest population of individuals had access to our industry leading, near painless, and non-invasive technology.”

Photograph: Thorne HealthTech, Inc.